Last reviewed · How we verify
nimotuzumab plus paclitaxel
Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division.
Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division. Used for Non-small cell lung cancer.
At a glance
| Generic name | nimotuzumab plus paclitaxel |
|---|---|
| Also known as | Combined with chemotherapy |
| Sponsor | Biotech Pharmaceutical Co., Ltd. |
| Drug class | Monoclonal antibody and taxane |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nimotuzumab binds to the EGFR, preventing it from interacting with its ligands and thereby inhibiting the receptor's downstream signaling pathways. Paclitaxel works by stabilizing microtubules, preventing cell division and ultimately leading to cell death.
Approved indications
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Fatigue
- Anemia
Key clinical trials
- Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC (PHASE2)
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (PHASE2)
- Adebrelimab Neoadjuvant Treatment for Resectable ESCC (NA)
- Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer (PHASE3)
- Neoadjuvant Treatment Modalities in Esophageal Cancer (PHASE3)
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer (PHASE2)
- Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II (PHASE2)
- Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nimotuzumab plus paclitaxel CI brief — competitive landscape report
- nimotuzumab plus paclitaxel updates RSS · CI watch RSS
- Biotech Pharmaceutical Co., Ltd. portfolio CI